NO20041180L - Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser - Google Patents

Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser

Info

Publication number: NO20041180L
Authority: NO; Norway
Prior art keywords: pyrrolopyrimidines; inhibition; agents; cysteine proteases; proteases
Prior art date: 2001-08-30

Application number

NO20041180A

Other languages

English (en)

Other versions

NO328890B1 (no

Inventor

Martin Missbach

Naoki Teno

Kenji Hayakawa

Genji Iwasaki

Claudia Betschart

Osamu Irie

Junichi Sakaki

Rene Lattmann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-30

Filing date

2004-03-19

Publication date

2004-03-19

2004-03-19 Application filed by Novartis Ag filed Critical Novartis Ag

2004-03-19 Publication of NO20041180L publication Critical patent/NO20041180L/no

2010-06-07 Publication of NO328890B1 publication Critical patent/NO328890B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20041180A 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse NO328890B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0121033.5A GB0121033D0 (en)	2001-08-30	2001-08-30	Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en)	2001-08-30	2002-08-29	Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (2)

Publication Number	Publication Date
NO20041180L true NO20041180L (no)	2004-03-19
NO328890B1 NO328890B1 (no)	2010-06-07

Family

ID=9921234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041180A NO328890B1 (no)	2001-08-30	2004-03-19	Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse

Country Status (30)

Country	Link
US (2)	US7452886B2 (no)
EP (1)	EP1423391B8 (no)
JP (1)	JP4629334B2 (no)
KR (1)	KR100695845B1 (no)
CN (1)	CN100372849C (no)
AR (1)	AR036374A1 (no)
AT (1)	ATE326469T1 (no)
AU (1)	AU2002333760B2 (no)
BR (1)	BR0212226A (no)
CA (1)	CA2458684C (no)
CY (1)	CY1105573T1 (no)
DE (1)	DE60211530T2 (no)
DK (1)	DK1423391T3 (no)
EC (1)	ECSP044998A (no)
ES (1)	ES2262888T3 (no)
GB (1)	GB0121033D0 (no)
HK (1)	HK1072254A1 (no)
HU (1)	HUP0401301A3 (no)
IL (3)	IL160367A0 (no)
MX (1)	MXPA04001935A (no)
MY (1)	MY157368A (no)
NO (1)	NO328890B1 (no)
NZ (1)	NZ531343A (no)
PE (1)	PE20030418A1 (no)
PL (1)	PL368280A1 (no)
PT (1)	PT1423391E (no)
RU (1)	RU2331644C2 (no)
TW (1)	TWI297690B (no)
WO (1)	WO2003020721A1 (no)
ZA (1)	ZA200401042B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030144234A1 (en) *	2001-08-30	2003-07-31	Buxton Francis Paul	Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
GB0220187D0 (en)	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
EP1575576A2 (en)	2002-09-24	2005-09-21	Novartis AG	Organic compounds
PE20050068A1 (es) *	2003-02-06	2005-03-11	Novartis Ag	2-cianopirrolopirimidinas como inhibidores de la catepsina s
GB0304640D0 (en) *	2003-02-28	2003-04-02	Novartis Ag	Organic compounds
WO2004092169A1 (ja) *	2003-04-18	2004-10-28	Ono Pharmaceutical Co., Ltd.	スピロピペリジン化合物およびその医薬用途
EP1797883A3 (en) *	2003-04-28	2007-08-01	Novartis AG	Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
WO2004096227A1 (en) *	2003-04-28	2004-11-11	Novartis Ag	Pharmaceutical compositon comprising a cathepsin s inhibitor and an opioid
AU2004236195A1 (en) *	2003-04-30	2004-11-18	Bayer Cropscience Ag	Phenyl substituted cyclic derivatives
WO2005011703A1 (en) *	2003-08-04	2005-02-10	Akzo Nobel N.V.	2-cyano-1,3,5-triazine-4,6-diamine derivatives
WO2005023810A1 (en) *	2003-09-10	2005-03-17	Virochem Pharma Inc.	Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
US20070197549A1 (en)	2004-02-18	2007-08-23	Astrazeneca Ab	Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
US20070197510A1 (en) *	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) *	2004-04-20	2007-07-01	Inke, S.A.	Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
CA2564953A1 (en) *	2004-05-03	2005-11-24	Janssen Pharmaceutica N.V.	Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en)	2004-06-11	2006-05-16	Akzo Nobel Nv	4-phenyl-pyrimidine-2-carbonitrile derivatives
US7951816B2 (en)	2004-08-27	2011-05-31	Ono Pharmaceutical Co., Ltd.	Compound containing basic group and use thereof
KR100651849B1 (ko) *	2005-02-01	2006-12-01	엘지전자 주식회사	세탁기
RU2424234C2 (ru) *	2005-08-05	2011-07-20	Ибриженикс Са	Новые ингибиторы цистеиновых протеаз и их терапевтическое применение
EA013816B1 (ru)	2005-09-01	2010-08-30	Арес Трейдинг С.А.	Лечение неврита зрительного нерва
TW200745055A (en) *	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en)	2005-09-23	2008-02-05	N.V. Organon	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) *	2005-10-26	2007-10-17	Smithkline Beecham Corp	Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
PT1961744E (pt)	2005-11-18	2013-05-15	Ono Pharmaceutical Co	Composto que contém um grupo básico e sua utilização
JP5475288B2 (ja) *	2005-12-05	2014-04-16	インサイト・コーポレイション	ラクタム化合物およびそれを用いる方法
US7687515B2 (en)	2006-01-17	2010-03-30	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
WO2007132846A1 (ja)	2006-05-16	2007-11-22	Ono Pharmaceutical Co., Ltd.	保護されていてもよい酸性基を含有する化合物およびその用途
CN101511802A (zh)	2006-09-13	2009-08-19	阿斯利康(瑞典)有限公司	螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
TW200911803A (en) *	2007-07-16	2009-03-16	Organon Nv	6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en)	2007-07-16	2011-04-26	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
KR20100090777A (ko)	2007-10-19	2010-08-17	아스트라제네카 아베	대사성 글루타메이트 수용체 (ｍｇｌｕｒ)의 조절제로서의 테트라졸 유도체
KR20180017232A (ko)	2008-06-20	2018-02-20	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
TW201035094A (en)	2009-01-16	2010-10-01	Organon Nv	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en)	2009-01-16	2011-09-27	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
MX2011013816A (es)	2009-06-29	2012-04-11	Incyte Corp	Pirimidinonas como inhibidores de pi3k.
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
PH12012501337A1 (en)	2009-12-30	2012-12-17	Arqule Inc	Substituted pyrrolo-aminopyrimidine compounds
WO2011086125A1 (en)	2010-01-15	2011-07-21	N.V. Organon	1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
WO2011130342A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
US8609672B2 (en)	2010-08-27	2013-12-17	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
EP3517630B1 (en)	2010-10-06	2022-01-19	Institució Catalana de Recerca i Estudis Avançats	Method for the diagnosis, prognosis and treatment of breast cancer metastasis
AR084366A1 (es)	2010-12-20	2013-05-08	Incyte Corp	N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY179332A (en)	2011-09-02	2020-11-04	Incyte Holdings Corp	Heterocyclylamines as pl3k inhibitors
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en)	2012-04-09	2013-10-16	Fundació Privada Institut de Recerca Biomèdica	Method for the prognosis and treatment of cancer metastasis
JP6172143B2 (ja) *	2012-04-17	2017-08-02	アステラス製薬株式会社	含窒素二環式芳香族へテロ環化合物
EP2859120B1 (en)	2012-06-06	2018-11-14	Fundació Institut de Recerca Biomèdica (IRB Barcelona)	Method for the diagnosis and prognosis of lung cancer metastasis
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014057357A2 (en)	2012-10-12	2014-04-17	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014184679A2 (en)	2013-03-15	2014-11-20	Inbiomotion S.L.	Method for the prognosis and treatment of renal cell carcinoma metastasis
KR20150122731A (ko)	2013-03-15	2015-11-02	펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나)	암 전이의 예후 및 치료 방법
JP6550045B2 (ja)	2013-10-09	2019-07-24	フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）ＦｕｎｄａｃｉｏＩｎｓｔｉｔｕｔＤｅＲｅｃｅｒｃａＢｉｏｍｅｄｉｃａ（ＩｒｂＢａｒｃｅｌｏｎａ）	乳がんに由来する骨の転移がんの予後診断および処置のための方法
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
KR20170093182A (ko)	2014-12-11	2017-08-14	인바이오모션 에스.엘.	인간 c-maf에 대한 결합 구성원
MD3262046T2 (ro)	2015-02-27	2021-03-31	Incyte Corp	Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
AU2017271385B2 (en)	2016-05-25	2023-10-05	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-MAF status
BR112020010192A2 (pt)	2017-11-22	2020-10-13	Inbiomotion S.L.	tratamento terapêutico de câncer de mama com base no status de c-maf
KR102054910B1 (ko) *	2017-12-19	2019-12-12	한림제약(주)	피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (en) *	2018-04-19	2019-10-23	F. Hoffmann-La Roche AG	Spiro compounds
CN112312904B (zh)	2018-04-16	2025-01-07	C4医药公司	螺环化合物
CN112469418A (zh)	2018-06-01	2021-03-09	因赛特公司	治疗pi3k相关病症的给药方案
WO2020201572A1 (en)	2019-04-05	2020-10-08	Université De Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) *	2021-04-22	2024-02-28	Protego Biopharma, Inc.	Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1251074B (de) *	1960-11-02	1967-09-28	J R Geigy A -G , Basel (Schweiz)	Selektives Herbizid
CH627919A5 (de)	1977-04-14	1982-02-15	Ciba Geigy Ag	Herbizide mittel.
US5958930A (en) *	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US5683999A (en) *	1995-03-17	1997-11-04	The Dupont Merck Pharmaceutical Company	Cyclic urea HIV protease inhibitors
HUP0001507A3 (en) *	1997-03-19	2002-01-28	Abbott Gmbh & Co Kg	Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
AU4710699A (en) *	1998-06-30	2000-01-17	Eli Lilly And Company	Bicyclic sPLA2 inhibitors
SK3842001A3 (en) *	1998-09-18	2002-04-04	Basf Ag	Pyrrolopyrimidines as protein kinase inhibitors (revised)
ES2208433T3 (es) *	1999-12-10	2004-06-16	Pfizer Products Inc.	Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas.
CA2402516A1 (en) *	2000-03-20	2001-09-27	Roopa Rai	Non-amidine containing protease inhibitors
NZ522217A (en)	2000-04-28	2004-04-30	Tanabe Seiyaku Co	Cyclic compounds

2001
- 2001-08-30 GB GBGB0121033.5A patent/GB0121033D0/en not_active Ceased
2002
- 2002-08-27 MY MYPI20023181A patent/MY157368A/en unknown
- 2002-08-28 AR ARP020103229A patent/AR036374A1/es unknown
- 2002-08-28 TW TW091119570A patent/TWI297690B/zh not_active IP Right Cessation
- 2002-08-29 PE PE2002000833A patent/PE20030418A1/es not_active Application Discontinuation
- 2002-08-29 CA CA002458684A patent/CA2458684C/en not_active Expired - Fee Related
- 2002-08-29 DK DK02797553T patent/DK1423391T3/da active
- 2002-08-29 NZ NZ531343A patent/NZ531343A/en not_active IP Right Cessation
- 2002-08-29 KR KR1020047003048A patent/KR100695845B1/ko not_active IP Right Cessation
- 2002-08-29 HU HU0401301A patent/HUP0401301A3/hu unknown
- 2002-08-29 WO PCT/EP2002/009663 patent/WO2003020721A1/en active Application Filing
- 2002-08-29 AT AT02797553T patent/ATE326469T1/de active
- 2002-08-29 IL IL16036702A patent/IL160367A0/xx unknown
- 2002-08-29 PT PT02797553T patent/PT1423391E/pt unknown
- 2002-08-29 PL PL02368280A patent/PL368280A1/xx not_active Application Discontinuation
- 2002-08-29 DE DE60211530T patent/DE60211530T2/de not_active Expired - Lifetime
- 2002-08-29 EP EP02797553A patent/EP1423391B8/en not_active Expired - Lifetime
- 2002-08-29 US US10/487,760 patent/US7452886B2/en not_active Expired - Fee Related
- 2002-08-29 RU RU2004109815/04A patent/RU2331644C2/ru not_active IP Right Cessation
- 2002-08-29 JP JP2003524991A patent/JP4629334B2/ja not_active Expired - Fee Related
- 2002-08-29 ES ES02797553T patent/ES2262888T3/es not_active Expired - Lifetime
- 2002-08-29 BR BR0212226-0A patent/BR0212226A/pt not_active Application Discontinuation
- 2002-08-29 MX MXPA04001935A patent/MXPA04001935A/es active IP Right Grant
- 2002-08-29 AU AU2002333760A patent/AU2002333760B2/en not_active Ceased
- 2002-08-29 CN CNB028168402A patent/CN100372849C/zh not_active Expired - Fee Related
2004
- 2004-02-09 ZA ZA200401042A patent/ZA200401042B/en unknown
- 2004-02-12 IL IL160367A patent/IL160367A/en not_active IP Right Cessation
- 2004-03-01 EC EC2004004998A patent/ECSP044998A/es unknown
- 2004-03-19 NO NO20041180A patent/NO328890B1/no not_active IP Right Cessation
2005
- 2005-05-20 HK HK05104226A patent/HK1072254A1/xx not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101095T patent/CY1105573T1/el unknown
2008
- 2008-09-25 US US12/237,896 patent/US20090054467A1/en not_active Abandoned
2009
- 2009-05-07 IL IL198643A patent/IL198643A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1072254A1 (en)	2005-08-19
PE20030418A1 (es)	2003-06-12
MXPA04001935A (es)	2004-06-15
ECSP044998A (es)	2004-04-28
GB0121033D0 (en)	2001-10-24
DK1423391T3 (da)	2006-09-25
CA2458684A1 (en)	2003-03-13
KR20040029123A (ko)	2004-04-03
US20090054467A1 (en)	2009-02-26
HUP0401301A3 (en)	2008-03-28
IL160367A0 (en)	2004-07-25
CN1549817A (zh)	2004-11-24
EP1423391B8 (en)	2007-12-12
KR100695845B1 (ko)	2007-03-20
NZ531343A (en)	2006-01-27
EP1423391B1 (en)	2006-05-17
CN100372849C (zh)	2008-03-05
IL160367A (en)	2009-12-24
EP1423391A1 (en)	2004-06-02
NO328890B1 (no)	2010-06-07
PT1423391E (pt)	2006-09-29
BR0212226A (pt)	2004-08-17
ZA200401042B (en)	2004-10-25
US7452886B2 (en)	2008-11-18
RU2331644C2 (ru)	2008-08-20
JP2005502683A (ja)	2005-01-27
AR036374A1 (es)	2004-09-01
CY1105573T1 (el)	2010-07-28
ATE326469T1 (de)	2006-06-15
PL368280A1 (en)	2005-03-21
DE60211530D1 (de)	2006-06-22
HUP0401301A2 (hu)	2004-10-28
CA2458684C (en)	2009-04-07
US20050054851A1 (en)	2005-03-10
AU2002333760B2 (en)	2007-01-04
JP4629334B2 (ja)	2011-02-09
DE60211530T2 (de)	2006-12-21
MY157368A (en)	2016-06-15
RU2004109815A (ru)	2005-10-20
IL198643A (en)	2010-12-30
WO2003020721A1 (en)	2003-03-13
TWI297690B (en)	2008-06-11
ES2262888T3 (es)	2006-12-01

Publication	Publication Date	Title
NO20041180L (no)	2004-03-19	Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser
NO20031065D0 (no)	2003-03-07	Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
NO20033399L (no)	2003-09-25	Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033593L (no)	2003-08-13	Kinazoliner som MMP-13 inhibitorer
EP1272467A4 (en)	2003-05-07	Cathepsin cysteine protease inhibitors
NO20033618L (no)	2003-10-15	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20043158L (no)	2004-09-16	Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
DK1666071T3 (da)	2008-01-07	Præparat til restenoseprofylakse
DE60238291D1 (de)	2010-12-30	Wafer-Haltevorrichtung
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20035087D0 (no)	2003-11-14	Anvendelse av HMG fragment som anti-inflammatoriske midler
AU2002305926A1 (en)	2002-10-08	Cysteine protease inhibitors
NO20035728D0 (no)	2003-12-19	Pyrrolopyrimidiner som proteinkinaseinhibitorer
DK1458447T3 (da)	2010-01-18	Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1442030T3 (da)	2006-12-27	Thiopen- og thiazolsulfonamider som antineoplastiske midler
FI20010558L (fi)	2002-09-20	Kappaleiden paikannus
DE60229764D1 (de)	2008-12-18	Entgratwerkzeug
NO20041968L (no)	2004-05-11	Anvendelse av cystationin
NO20033234L (no)	2003-09-22	Karotenoider som antihypertensjonsmidler
ATE330603T1 (de)	2006-07-15	Benzothiazolderivaten
NO20042057L (no)	2004-05-18	Fosfonsyreforbindelser som inhibitorer av serinproteaser
NO20030820L (no)	2003-04-22	Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
EP1450810A4 (en)	2005-11-30	XANTHINE INHIBITION
AU2001253633A1 (en)	2001-10-30	Inhibitors of the ice/ced-3 family of cysteine proteases

Legal Events

Date	Code	Title	Description
2012-03-26	MM1K	Lapsed by not paying the annual fees